BCL2L1 and lymphoid leukemia: Apigenin when used in combination with etoposide was shown to synergistically decrease the expression of BCLX gene and protein levels in Jurkat lymphoid leukaemia cells, compared to the vehicle control and drugs alone (P ≤ 0.05) (Fig. 1A).